Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4 Study to Compare US Marketed Creon Drug Product With Drug Product Manufactured With a Modernized Process at an Alternate Manufacturing Site and With Drug Product Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Subjects With EPI Due to Cystic Fibrosis

NCT03924947 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03924947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03924947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4 Study to Compare US Marketed Creon Drug Product With Drug Product Manufactured With a Modernized Process at an Alternate Manufacturing Site and With Drug Product Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Subjects With EPI Due to Cystic Fibrosis
Lead sponsor
AbbVie
Phase
Phase 4
Overall status
Completed
Start date
October 23, 2019
Completion date
July 11, 2022
Enrollment
36 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis